Skip to main content Back to Top


Mupirocin Calcium 2% Cream

Products Affected - Description

    • Bactroban topical cream, GlaxoSmithKline, 2%, 15 gm tube, 1 count, NDC 00029-1527-22
    • Bactroban topical cream, GlaxoSmithKline, 2%, 30 gram tube, 1 count, NDC 00029-1527-25

Reason for the Shortage

    • GlaxoSmithKline is looking for an alternative supply source.
    • Glenmark has mupirocin cream available.
    • Prasco discontinued mupirocin calcium 2% cream in February 2016.

Available Products

    • Mupirocin calcium topical cream, Glenmark, 2%, 15 gram tube, 1 count, NDC 68462-0564-17
    • Mupirocin calcium topical cream, Glenmark, 2%, 30 gram tube, 1 count, NDC 68462-0564-35

Estimated Resupply Dates

    • GlaxoSmithKline has Bactroban 2% cream in 15 gram and 30 gram sizes on long-term back order and the company cannot estimate a release date.


Updated November 20, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created September 4, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins